Barrett's esophagus: proton pump inhibitors and chemoprevention I

G. Triadafilopoulos; A. Taddei; P. Bechi; G. Freschi; M.N. Ringressi; D.R. Degli'Innocenti; F. Castiglione; E. Masini; M. Majewski; G. Wallner; J. Sarosiek; John F. Dillon; R.C. Mccallum; K. Dvorak; A. Goldman; P. Woodland; D. Sifrim; J.E. Richter; M. Vieth; H. Neumann; C. Langner; N. Ishimura; Y. Amano; V.N. Felix

doi:10.1111/j.1749-6632.2011.06047.x

Barrett's esophagus: proton pump inhibitors and chemoprevention I

G. Triadafilopoulos, A. Taddei, P. Bechi, G. Freschi, M.N. Ringressi, D.R. Degli'Innocenti, F. Castiglione, E. Masini, M. Majewski, G. Wallner, J. Sarosiek, John F. Dillon, R.C. Mccallum, K. Dvorak, A. Goldman, P. Woodland, D. Sifrim, J.E. Richter, M. Vieth, H. NeumannC. Langner, N. Ishimura, Y. Amano, V.N. Felix

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

The following on proton pump inhibitors and chemoprevention in Barrett's esophagus includes commentaries on normalization of esophageal refluxate; the effects of 5-HT agonists on EGF secretion and of lubripristone on chloride channels agents; the role of Campylobacter toxin production; the deleterious effects of unconjugated bile acids; the role of baclofen in nonacid reflux; the threshold for adequate esophageal acid exposure; the effects of proton pump inhibitor (PPI) therapy on normalization of esophageal pH and on cell proliferation; the role of the phenotype of cellular proliferation on the effects of PPI therapy; and the value of Symptom Index and Symptom Association Probability in the evaluation of potential response to treatment. © 2011 New York Academy of Sciences.

Original language	English
Pages (from-to)	93-113
Number of pages	21
Journal	Annals of the New York Academy of Sciences
Volume	1232
Issue number	1
DOIs	https://doi.org/10.1111/j.1749-6632.2011.06047.x
Publication status	Published - Sept 2011
Event	10th OESO World Congress on Barrett's Esophagus - Boston, United States Duration: 28 Aug 2010 → 31 Aug 2010 http://www.oeso.org/pastcongresses/boston-oeso2010.html

Access to Document

10.1111/j.1749-6632.2011.06047.x

Cite this

Triadafilopoulos, G., Taddei, A., Bechi, P., Freschi, G., Ringressi, M. N., Degli'Innocenti, D. R., Castiglione, F., Masini, E., Majewski, M., Wallner, G., Sarosiek, J., Dillon, J. F., Mccallum, R. C., Dvorak, K., Goldman, A., Woodland, P., Sifrim, D., Richter, J. E., Vieth, M., ... Felix, V. N. (2011). Barrett's esophagus: proton pump inhibitors and chemoprevention I. Annals of the New York Academy of Sciences, 1232(1), 93-113. https://doi.org/10.1111/j.1749-6632.2011.06047.x

@article{412ecc71183143c4821d7c4fa8a036a9,

title = "Barrett's esophagus: proton pump inhibitors and chemoprevention I",

abstract = "The following on proton pump inhibitors and chemoprevention in Barrett's esophagus includes commentaries on normalization of esophageal refluxate; the effects of 5-HT agonists on EGF secretion and of lubripristone on chloride channels agents; the role of Campylobacter toxin production; the deleterious effects of unconjugated bile acids; the role of baclofen in nonacid reflux; the threshold for adequate esophageal acid exposure; the effects of proton pump inhibitor (PPI) therapy on normalization of esophageal pH and on cell proliferation; the role of the phenotype of cellular proliferation on the effects of PPI therapy; and the value of Symptom Index and Symptom Association Probability in the evaluation of potential response to treatment. {\textcopyright} 2011 New York Academy of Sciences.",

author = "G. Triadafilopoulos and A. Taddei and P. Bechi and G. Freschi and M.N. Ringressi and D.R. Degli'Innocenti and F. Castiglione and E. Masini and M. Majewski and G. Wallner and J. Sarosiek and Dillon, {John F.} and R.C. Mccallum and K. Dvorak and A. Goldman and P. Woodland and D. Sifrim and J.E. Richter and M. Vieth and H. Neumann and C. Langner and N. Ishimura and Y. Amano and V.N. Felix",

note = "MEDLINE{\textregistered} is the source for the MeSH terms of this document.; 10th OESO World Congress on Barrett's Esophagus ; Conference date: 28-08-2010 Through 31-08-2010",

year = "2011",

month = sep,

doi = "10.1111/j.1749-6632.2011.06047.x",

language = "English",

volume = "1232",

pages = "93--113",

journal = "Annals of the New York Academy of Sciences",

issn = "0077-8923",

publisher = "Wiley",

number = "1",

url = "http://www.oeso.org/pastcongresses/boston-oeso2010.html",

}

Triadafilopoulos, G, Taddei, A, Bechi, P, Freschi, G, Ringressi, MN, Degli'Innocenti, DR, Castiglione, F, Masini, E, Majewski, M, Wallner, G, Sarosiek, J, Dillon, JF, Mccallum, RC, Dvorak, K, Goldman, A, Woodland, P, Sifrim, D, Richter, JE, Vieth, M, Neumann, H, Langner, C, Ishimura, N, Amano, Y & Felix, VN 2011, 'Barrett's esophagus: proton pump inhibitors and chemoprevention I', Annals of the New York Academy of Sciences, vol. 1232, no. 1, pp. 93-113. https://doi.org/10.1111/j.1749-6632.2011.06047.x

TY - JOUR

T1 - Barrett's esophagus

T2 - 10th OESO World Congress on Barrett's Esophagus

AU - Triadafilopoulos, G.

AU - Taddei, A.

AU - Bechi, P.

AU - Freschi, G.

AU - Ringressi, M.N.

AU - Degli'Innocenti, D.R.

AU - Castiglione, F.

AU - Masini, E.

AU - Majewski, M.

AU - Wallner, G.

AU - Sarosiek, J.

AU - Dillon, John F.

AU - Mccallum, R.C.

AU - Dvorak, K.

AU - Goldman, A.

AU - Woodland, P.

AU - Sifrim, D.

AU - Richter, J.E.

AU - Vieth, M.

AU - Neumann, H.

AU - Langner, C.

AU - Ishimura, N.

AU - Amano, Y.

AU - Felix, V.N.

N1 - MEDLINE® is the source for the MeSH terms of this document.

PY - 2011/9

Y1 - 2011/9

N2 - The following on proton pump inhibitors and chemoprevention in Barrett's esophagus includes commentaries on normalization of esophageal refluxate; the effects of 5-HT agonists on EGF secretion and of lubripristone on chloride channels agents; the role of Campylobacter toxin production; the deleterious effects of unconjugated bile acids; the role of baclofen in nonacid reflux; the threshold for adequate esophageal acid exposure; the effects of proton pump inhibitor (PPI) therapy on normalization of esophageal pH and on cell proliferation; the role of the phenotype of cellular proliferation on the effects of PPI therapy; and the value of Symptom Index and Symptom Association Probability in the evaluation of potential response to treatment. © 2011 New York Academy of Sciences.

AB - The following on proton pump inhibitors and chemoprevention in Barrett's esophagus includes commentaries on normalization of esophageal refluxate; the effects of 5-HT agonists on EGF secretion and of lubripristone on chloride channels agents; the role of Campylobacter toxin production; the deleterious effects of unconjugated bile acids; the role of baclofen in nonacid reflux; the threshold for adequate esophageal acid exposure; the effects of proton pump inhibitor (PPI) therapy on normalization of esophageal pH and on cell proliferation; the role of the phenotype of cellular proliferation on the effects of PPI therapy; and the value of Symptom Index and Symptom Association Probability in the evaluation of potential response to treatment. © 2011 New York Academy of Sciences.

UR - http://www.scopus.com/inward/record.url?scp=80053181729&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2011.06047.x

DO - 10.1111/j.1749-6632.2011.06047.x

M3 - Article

C2 - 21950809

SN - 0077-8923

VL - 1232

SP - 93

EP - 113

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

IS - 1

Y2 - 28 August 2010 through 31 August 2010

ER -

Barrett's esophagus: proton pump inhibitors and chemoprevention I

Abstract

Access to Document

Other files and links

Fingerprint

Cite this